Barely three months after reporting its outstanding clinical results for brentuximab vedotin at the annual meeting of the American Society for Hematology (ASH) in December, Seattle Genetics Inc. submitted its biologics license application to the FDA, petitioning for an accelerated six-month approval timeline.